Clinical implications of p53 mutations

被引:0
|
作者
R. R. Wallace-Brodeur
S. W. Lowe
机构
[1] Cold Spring Harbor Laboratory,
[2] 1 Bungtown Rd.,undefined
[3] P.O. Box 100,undefined
[4] Cold Spring Harbor (New York 11724,undefined
[5] USA),undefined
[6] Fax +1 516 367 8454,undefined
[7] e-mail: lowe@cshl.org,undefined
关键词
Key words. Apoptosis; chemotherapy; prognosis; tumor suppressor; cancer genetics; clinical outcome.;
D O I
暂无
中图分类号
学科分类号
摘要
The ultimate goal of basic cancer research is to provide a theoretical foundation for rational approaches to improve cancer therapy. Our extensive insight into the biology of the p53 tumour suppressor and the clinical behaviour of tumours harbouring p53 mutations indicates that information concerning p53 will be useful in diagnosis and prognosis, and may ultimately produce new therapeutic strategies. At the same time, efforts to understand the clinical implications of p53 mutations have revealed conceptual and technical limitations in translating basic biology to the clinic. The lessons learned from p53 may lay the groundwork for future efforts to synthesize cancer gene function, cancer genetics and cancer therapy.
引用
收藏
页码:64 / 75
页数:11
相关论文
共 50 条
  • [21] CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    RUTZ, HP
    MIRIMANOFF, RO
    NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12): : 864 - 865
  • [22] Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
    Riva, Elena
    Zampini, Matteo
    Alberto, Termanini
    Dall'Olio, Lorenzo
    Merlotti, Alessandra
    Kulasekararaj, Austin
    Calvi, Michela
    Di Vito, Clara
    Rahal, Daoud
    Bonometti, Arturo
    Croci, Giorgio
    Boveri, Emanuela
    Gianelli, Umberto
    Ponzoni, Maurilio
    Russo, Antonio
    Tinterri, Benedetta
    Re, Francesca
    Sauta, Elisabetta
    Saba, Elena
    Travaglino, Erica
    Ubezio, Marta
    Campagna, Alessia
    Lanino, Luca
    Maggioni, Giulia
    Tentori, Cristina Astrid
    Milanesi, Chiara
    Manes, Nicla
    D'Amico, Saverio
    Ficara, Francesca
    Crisafulli, Laura
    Mavilio, Domenico
    Lugli, Enrico
    Santoro, Armando
    Diez-Campelo, Maria
    Sanz, Guillermo
    Sole, Francesc
    Platzbecker, Uwe
    Santini, Valeria
    Kordasti, Shahram
    Fenaux, Pierre
    Haferlach, Torsten
    Remondini, Daniel
    Gastone, Castellani
    Della Porta, Matteo G.
    BLOOD, 2022, 140 : 4001 - 4004
  • [23] CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE
    HARRIS, CC
    HOLLSTEIN, M
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18): : 1318 - 1327
  • [24] P53 MUTATIONS IN HUMAN CANCERS
    HOLLSTEIN, M
    SIDRANSKY, D
    VOGELSTEIN, B
    HARRIS, CC
    SCIENCE, 1991, 253 (5015) : 49 - 53
  • [25] P53 MUTATIONS IN HUMAN CANCER
    MILLER, C
    KOEFFLER, HP
    LEUKEMIA, 1993, 7 : S18 - S21
  • [26] The spectrum of mutations at the p53 locus
    Levine, AJ
    Wu, MC
    Chang, A
    Silver, A
    Atttiyeh, EF
    Lin, J
    Epstein, CB
    CANCER PREVENTION: FROM THE LABORATORY TO THE CLINIC: IMPLICATIONS OF GENETIC, MOLECULAR, AND PREVENTIVE RESEARCH, 1995, 768 : 111 - 128
  • [27] MUTATIONS IN THE P53 ANTIONCOGENE IN ASTROCYTOMAS
    HUNTER, SB
    VARMA, V
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1992, 51 (03): : 333 - 333
  • [28] P53 MUTATIONS IN CERVICAL ADENOCARCINOMA
    TENTI, P
    PAVANELLO, S
    ROMAGNOLI, S
    ZAPPATORE, R
    MACCARINI, U
    ZARA, C
    GIUNTA, P
    MIGLIORA, P
    SILINI, E
    RANZANI, GN
    CARNEVALI, L
    LABORATORY INVESTIGATION, 1995, 72 (01) : A98 - A98
  • [29] P53 MUTATIONS - GAINS OR LOSSES
    MICHALOVITZ, D
    HALEVY, O
    OREN, M
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1991, 45 (01) : 22 - 29
  • [30] GAIN OF FUNCTION MUTATIONS IN P53
    DITTMER, D
    PATI, S
    ZAMBETTI, G
    CHU, S
    TERESKY, AK
    MOORE, M
    FINLAY, C
    LEVINE, AJ
    NATURE GENETICS, 1993, 4 (01) : 42 - 46